ShouTi Revenue and Competitors

Location

#1417

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • ShouTi's estimated annual revenue is currently $18.3M per year.(i)
  • ShouTi's estimated revenue per employee is $155,000
  • ShouTi's total funding is $174M.

Employee Data

  • ShouTi has 118 Employees.(i)
  • ShouTi grew their employee count by 64% last year.

ShouTi's People

NameTitleEmail/Phone
1
CSO, General ManagerReveal Email/Phone
2
General Manager & PresidentReveal Email/Phone
3
SVP Clinical Development OperationsReveal Email/Phone
4
SVP Cardiopulmonary Clinical DevelopmentReveal Email/Phone
5
SVP Head BiologyReveal Email/Phone
6
Chief Medical OfficerReveal Email/Phone
7
Chief Business OfficerReveal Email/Phone
8
Chief Financial OfficerReveal Email/Phone
9
Chief Technology OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is ShouTi?

ShouTi is a global drug discovery company focused on accelerating the world’s transition to accessible and effective medicines. The Company’s goal is to transform expensive, less stable, difficult to transport or administer therapeutics into innovative, rationally-designed and best-in-class small molecule medicines that cost less to produce and make them accessible to patients globally.

keywords:N/A

$174M

Total Funding

118

Number of Employees

$18.3M

Revenue (est)

64%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ShouTi News

2022-03-22 - ShouTi Appoints Sharon Tetlow to Board of Directors

SAN FRANCISCO & SHANGHAI--(BUSINESS WIRE)--ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$17.1M118-14%$131.2M
#2
$16.5M118-14%$107M
#3
$24.1M118-3%$20.3M
#4
$27.6M118-10%N/A
#5
$16.5M118-4%N/A